

JFW

**CERTIFICATE OF MAILING**

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 14, 2004.

Ronald J. Ricc

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

In the Application of :  
Prasad DEVARAJAN, et al. : Confirmation No.: 2792  
Serial No.: 10/811,130 : Art Unit: 1653  
Filing Date: March 26, 2004 :  
For: **A Method and Kit for Detecting the Early Onset of  
Renal Tubular Cell Injury**

**INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.56, 1.97  
AND 1.98 (WITHIN 3 MONTHS OF FILING OR PRIOR TO  
FIRST OFFICE ACTION)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.56, 1.97, and 1.98, Applicants request the Examiner to make of record the documents listed on the attached PTO/SB/08 form. In accordance with MPEP 609, the Examiner is requested to initial each document listed on the attached PTO/SB/08 form in the space provided, make a copy of the initialed form, and return the copy to Applicants' attorney.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This paper and the enclosed documents are being submitted in accordance with 37 CFR 1.97(b), i.e., within three (3) months of the application filing date or prior to a first Office Action on the merits. Therefore, no fee is believed to be due.

Respectfully submitted,  
For: Prasad DEVARAJAN, et al.

By: Ronald J. Richter  
Ronald J. Richter  
Attorney for Applicants  
Registration No. 52,408  
(513) 229-0383 (voice)  
(513) 229-0683 (facsimile)  
Customer Number 26868

October 14, 2004



# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/811,130
Filing Date	03/26/2004
First Named Inventor	Prasad Devarajan
Art Unit	1653
Examiner Name	
Attorney Docket Number	CHM-015

Sheet	1	of	2
-------	---	----	---

## **U.S. PATENT DOCUMENTS**

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				
		US-	4,632,901	12/30/1986	Valkers et al.	
		US-	4,870,007	09/26/1989	Smith-Lewis	
		US-	5,273,743	12/28/1993	Ahlem et al.	
		US-	5,656,503	08/12/1997	May et al.	
		US-	6,500,627	12/31/2002	O'Connor et al.	

## **FOREIGN PATENT DOCUMENTS**

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s) volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Muramatsu, Y., Tsujie, M., Kohda, Y., Pham, B., Perantoni, A.O., Zhao, H., Jo, S-K, Yuen, PST, Craig, L., Hu, X., Star, R.A. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int., 62: 1601-1610, 2002.	
		Yoshida, T., Kurella, M., Beato, F., Min, H., Ingelfinger, J.R., Stears, R.L., Swinford, R.D., Gullans, S.R., Tang, S-S. Monitoring changes in gene expression in renal ischemia-reperfusion in the art. Kidney Int., 61: 1646-1654, 2002.	
		Supavekin, S., Zhanh, W., Kuchelapati, R., Kaskel, F.J., Moore, L.C., Devarajan, P. Differential gene expression following early renal ischemia-reperfusion. Kidney Int., 63: 1714-1724, 2003.	
		Nogae, S., Miyazaki, M., Kobayasji, N., Siato, T., Abe, K., Saito, H., Nakane, P.K., Nakanishi, Y., Koji, T. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: Possible involvement of Fas. J. Am. Soc. Nephrol., 9: 620-631, 1998.	
		Daemen, MARC, Van de Ven MWCM, Heineman, E., Buurman, W.A. Involvement of endogenous interleukin-10 and tumor necrosis factor- $\alpha$ in renal ischemia-reperfusion injury. Transplantation, 67: 792-800, 1999.	
		Kelly, K.J., Plotkin, Z., Dagher, P.C., Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury. J. Clin. Invest., 108: 1291-1298, 2001.	
		Burne, N.J., Rabb, H. Pathophysiological contributions of fucosyltransferases in renal ischemia reperfusion injury. J. Immunol., 169: 2648-2652, 2002.	
		Feldenberg, L.R., Thevananther, S., del Rio, M., DeLeon, M., Devarajan, P. Partial ATP deletion induces Fas- and caspase-mediated apoptosis in MDCK cells. Am. J. Physiol., 276 (Renal physiol 45): F837-F846, 1999.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/811,130
				Filing Date	03/26/2004
				First Named Inventor	Prasad Devarajan
				Art Unit	1653
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	CHM-015

	Devarajan, P., DeLeon, M., Talasazan, F., Schoenfeld, A.R., Davidowitz, E.J., Burk, R.D. The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. <i>J. Biol. Chem.</i> , 276: 40599-40605, 2001.	
	Yang, J., Goetz, D., Li, J-Y, Wand, W., Mori, K., Setlik, D., Du, T., Erdjument-Bromage, H., Tempst, P., Strong, R., Barasch, J. An iron delivery pathway mediated by a lipocalin. <i>Mol. Cell.</i> , 10: 1045-1056, 2002.	
	Molitoris, B.A., Weinberg, J.M., Venkatachalam, M.A., Zager, R.A., Nath, K.A., Goligorsky, M.S. Acute renal failure II. Experimental models of acute renal failure: imperfect but indispensable. <i>Am. J. Physiol. Renal Physiol.</i> , 278:F1-F12, 2000.	
	Kjeldsen, L., Cowland, J.B., Borregaard, N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. <i>Biochim. Biophys. Acta</i> , 1482: 272-283, 2000.	
	Kjeldsen, L., et al. Characterization of two ELISAs for NGAL, a newly described lipocalin in human neutrophils. <i>J. of Immunological Methods</i> , 198: 155-16, 1996.	
	Megyesi, J., Safirstein, R.L., Price, P.M. Induction of p21 WAF1/CIP/SD1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. <i>J. Clin. Invest.</i> , 101: 777-782, 1998.	
	Shiraishi, F., Curtis, L.M., Truong, L., Poss, K., Visner, G.A., Madsen, K., Nick, H.S., Agarwal, A. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. <i>Am. J. Physiol.</i> , 278: F726-F736, 2000.	
	Ramesh, G., Reeves, W.B. TNF- $\alpha$ mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. <i>J. Clin. Invest.</i> , 110: 835-842, 2002.	
	Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., Deverajan, P. Identification of NGAL as a novel urinary biomarker for ischemic injury. <i>J. Am. Soc. Nephrol.</i> , 14: 2534-2543, 2003.	
	Tsuruya, K., Ninomiya, T., Tokumoto, M., Hirakawa, M., Masutani, K., Taniguchi, M., Fukuda, K., Kanai, H., Kishihara, K., Hirakata, H., Iida, M. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. <i>Kidney Int.</i> , 63: 72-82, 2003.	
	Bundgaard, J., Sengelov, H., Borregaard, N., Kjeldsen, L. Molecular cloning and expression of a cDNA encoding Ngal: a lipocalin expressed in human neutrophils. <i>Biochem. Biophys. Res. Commun.</i> , 202: 1468-1475, 1994.	
	Del Rio, M., Imam, A., DeLeon, M., Gomez, G., Mishra, J., Ma, Q., Parikh, S., Deverajan, P. The death domain of kidney ankyrin interacts with Fas and promotes Fas-mediated cell death in renal epithelia. <i>J. Am. Soc. Nephrol.</i> , 15: 41-51, 2004.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--